MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

Search

Ipsen SA.

Ouvert

SecteurFinance

108.8 2.74

Résumé

Variation du prix de l'action

24h

Actuel

Min

105.5

Max

109.6

Chiffres clés

By Trading Economics

Revenu

-118M

114M

Ventes

71M

1.8B

P/E

Moyenne du Secteur

24.918

22.015

Rendement du dividende

1.12

Marge bénéficiaire

6.249

Employés

5,358

EBITDA

228M

710M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+16.14% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.12%

3.90%

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

8.8B

Ouverture précédente

106.06

Clôture précédente

108.8

Sentiment de l'Actualité

By Acuity

44%

56%

191 / 542 Classement par Finance

Score Technique

By Trading Central

Confiance

Bearish Evidence

Ipsen SA. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 déc. 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Comparaison

Variation de prix

Ipsen SA. prévision

Objectif de Prix

By TipRanks

16.14% hausse

Prévisions sur 12 Mois

Moyen 123.57 EUR  16.14%

Haut 145 EUR

Bas 110 EUR

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

7 ratings

2

Achat

4

Maintien

1

Vente

Score Technique

By Trading Central

105.5 / 108.6Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

191 / 542Classement par Finance

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.